<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1006245399
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DYSPORT 500U VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        intramuscular, subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        947.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Ipsen Biopharm Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Ipsen Biopharm Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Ipsen Limited 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M03AX01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dysport is a toxin produced by <em>Clostridium botulinum</em> bacteria. The toxin works by stopping muscles contracting. It does this by preventing the release of a chemical in between the nerves and muscles which would normally make the muscles contract. This helps to reduce some of the abnormal muscle contractions known as spasms.</p><p>Dysport is used in adults to treat muscle spasms</p><ul><li>around the eyes</li><li>in the face</li><li>in the neck and shoulders</li><li>in the arm</li></ul><p>Dysport is also used to treat spasms in the legs of children (aged two years or older) with cerebral palsy, to improve their walking.</p><p>You may also need to have physiotherapy</p><p>Dysport can also be used to prevent the muscles which cause frown lines from contracting.&nbsp; This muscle relaxation is temporary and gradually wears off. Some people are distressed when lines appear on their face. Dysport can be used in adults under 65 years to temporarily improve the appearance of any moderate to severe glabellar lines (these are the vertical frown lines between the eyebrows).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Dysport if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are aware you are allergic (hypersensitive) to <em>Clostridium botulinum </em>toxin A or to any of the ingredients of Dysport</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an infection at the proposed site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis</p><p><strong>Take special care with Dysport&reg;</strong></p><p>There are increased risks of having Dysport injections under any of these circumstances.</p><p>Tell your doctor if<strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any history of bronchitis, pneumonia or problems with breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an allergic reaction to a botulinum toxin in the past</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have other problems or diseases that affect your muscles e.g. myasthenia gravis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you bleed easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had surgery on your face, or are likely to undergo facial surgery or other types of surgery soon (if you are considering treatment for glabellar lines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you had no significant improvement of your lines after your last treatment (if you are considering treatment for glabellar lines)</p><p>&nbsp;</p><p>Important information about one of the ingredients of Dysport&reg;</p><p>Dysport contains a small amount of albumin which has been obtained from human blood. The risk of passing on infections from blood cannot be eliminated completely when using human blood or products made from human blood.</p><p><strong>&nbsp;</strong></p><p><strong>Taking other medicines:</strong></p><p>&nbsp;</p><p>Please tell your doctor if you are taking any antibiotics for an infection (e.g. aminoglycosides such as gentamicin or amikacin) or muscle relaxing drugs. Some of these medicines may increase the effect of Dysport.</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Pregnancy and Breast-feeding</strong></p><p>Dysport is not recommended during pregnancy, unless clearly necessary.</p><p>Dysport is not recommended in breast-feeding women.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding you should ask your doctor for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Use in children</strong></p><p>&nbsp;</p><p>Dysport should not be used in children younger than 2 years of age. Dysport is not suitable for the treatment of glabellar lines in patients under the age of 18.&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Dysport may cause muscle weakness or problems with your vision.</p><p>If you experience any of these effects, do not drive or use any machines.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will give you your injection and decide how often you need treatment. This will depend on what you are being treated for.</p><p>A vial of Dysport should be used only for you and only for a single treatment session.</p><p>&nbsp;</p><p><strong>For treatment of muscle spasms in your <em>arm:</em></strong></p><p>The dose of Dysport will normally be 1000 units and should not exceed this dose. The doctor may divide the amount between the affected arm muscles.&nbsp; Your muscle spasms should normally improve within 2 weeks. Injections will usually be given about every 12 to 16 weeks.</p><p>&nbsp;</p><p><strong>For treatment of muscle spasms in your <em>neck and shoulder:</em></strong></p><p>The first dose of Dysport will normally be 500 units. The doctor will divide this amount into a number of places in the neck, probably into 2 or 3 of the neck muscles most affected by the condition. A smaller amount may be given to very underweight or elderly patients. Your muscle spasms should improve within 1 week. Further injections (250-1000 units) will be given about every 16 weeks depending on how long the effect lasts or as required to maintain a response, but not more frequently than every 12 weeks. The maximum dose should not exceed 1000 units.</p><p>&nbsp;</p><p><strong>For treatment of muscle spasm around your <em>eyes:</em></strong></p><p>The first injection will usually be 40 units per eye. The medicine will be injected just under the skin at various sites around the eye. If only one eye is affected the doctor will only give injections of Dysport around this eye. Injections will be given about every 12 weeks depending on how long the effects last. On the next visit, the amount of Dysport given may be increased to a maximum of 120 units per eye.</p><p>&nbsp;</p><p><strong>For treatment of muscle spasm in your <em>face:</em></strong></p><p>The doctor will give you injections on the side of your face that is affected. The first injection will usually be 120 units. Injections will be given about every 12 weeks depending on how long the effects last. Your next injections of Dysport may be reduced to 80 or 60 units.</p><p>&nbsp;</p><p><strong>For treatment of a child with cerebral palsy with muscle spasms in their <em>legs:</em></strong></p><p>The first dose of Dysport will be 20 units for each kg of the child&rsquo;s body weight. The doctor will divide the amount between both lower leg muscles. If only one leg is affected by spasms, the doctor will only give injections of 10 units per kg in this leg. Injections will be given about every 12 to 16 weeks. The dose your doctor gives the child could change depending on how they respond. The maximum dose should not exceed 1000 units.</p><p>&nbsp;</p><p><strong>For temporary improvement of <em>glabellar lines:</em></strong></p><p>Dysport should only be administered by physicians with appropriate qualifications and expertise in this treatment and having the required equipment.&nbsp;</p><p>Your doctor will prepare and give the injections. A vial of Dysport should be used only for you and only for a single treatment session.</p><p>The recommended dose is 50 units, injected as 10 units at each of 5 injection sites in your forehead in the area above your nose and eyebrows.</p><p>The units used for different botulinum toxin products are not the same.&nbsp;</p><p>The effect of the treatment on the severity of your glabellar lines should be noticeable in 2 to 3 days. The interval between treatments with Dysport will be decided by your doctor. You should not have treatment more often than every 12 weeks.</p><p>&nbsp;</p><p><strong>If you are given more Dysport&reg; than you should</strong></p><p>&nbsp;</p><p>If you are given more Dysport than you need, muscles other than the ones that were injected may begin to feel weak. This may not happen straightaway. If this happens, speak to your doctor immediately. Seek urgent medical help if you have difficulty breathing, swallowing or speaking.</p><p>&nbsp;</p><p><strong>If you forget an injection of Dysport&reg;</strong></p><p>&nbsp;</p><p>Nothing will happen if an injection is missed other than some of the spasm or muscle stiffness may return. Tell your doctor and he will decide when the next injection is needed.</p><p>If you stop taking Dysport&reg;</p><p>Your muscle spasms will return to the way they were before treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Dysport can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Tell your doctor <strong>immediately</strong> if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any problems swallowing, breathing or with your speech</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you develop difficulty in breathing with or without swelling of the face, lips, tongue and /or throat, redness of the skin or an itchy lumpy rash (urticaria). This may mean you are having an allergic reaction to Dysport.</p><p>The chance of having a side effect is described by the following groups:</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>How often it occurs</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Occurs in more than 1 in 10 patients treated</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>in less than 1 in 10 patients treated</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>in less than 1 in 100 patients treated</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>in less than 1 in 1000 patients treated</p></td></tr></tbody></table><p>&nbsp;</p><p>Some side effects may occur in any patient treated with Dysport whilst other side effects may depend on the condition being treated. Make sure you read all the sections that apply to you.</p><p>&nbsp;</p><p><strong>Treatment of any condition <em>(all patients)</em></strong></p><p>&nbsp;</p><p>Side effects that have occurred include<strong>:</strong></p><p>Common:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising, or pain around the site where the injection was given or a burning sensation at the time the injection is given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalised weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms&nbsp;</p><p>&nbsp;</p><p>Uncommon: Itching</p><p>&nbsp;</p><p>Rare: Skin rashes and muscle weakness</p><p>&nbsp;</p><p>Other side effects related to the spread of Dysport away from the site of administration have also been reported (worsened muscle weakness, difficulty with swallowing or breathing which in very rare cases have been fatal).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Treatment of muscle spasms in the <em>arm</em>:</strong></p><p>&nbsp;</p><p>Side effects that have occurred include:</p><p>Common:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arm muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accidental injury/falls</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in swallowing</p><p>&nbsp;</p><p><strong>Treatment of muscle spasms in the <em>eyes or face</em></strong></p><p><strong>&nbsp;</strong></p><p>Side effects that have occurred include:</p><p><strong>&nbsp;</strong></p><p>Very common:</p><ul><li>Drooping eyelids</li></ul><p>&nbsp;</p><p>Common:</p><ul><li>Dry eyes</li><li>Double vision</li><li>More tears than usual</li><li>Swelling of the eyelid</li><li>Facial muscle weakness</li></ul><p>&nbsp;</p><p>Uncommon:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial paralysis</p><p>&nbsp;</p><p>Rare:</p><ul><li>Difficulty in moving the eye</li><li>The edge of the eyelid may turn in towards the eyeball and the eye muscles may become paralysed</li></ul><p>&nbsp;</p><p>Tell your doctor <strong>immediately </strong>if you notice very dry eyes.</p><p>&nbsp;</p><p><strong>Treatment of muscle spasms in the <em>neck or shoulders</em>:</strong></p><p>&nbsp;</p><p>Side effects that have occurred include:</p><p>Very common<strong>: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness</p><ul><li>Difficulty in swallowing. This side effect may be expected to resolve within 2 to 4 weeks.</li><li>Dry mouth</li></ul><p>Common:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision or other problems seeing clearly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neck pain</p><ul><li>Weakness of face muscles</li><li>Musculoskeletal pain</li><li>Muscle pain</li><li>Pain in the hands and fingers</li><li>Stiff muscle</li><li>Shortness of breath</li><li>A change to the tone of the voice</li></ul><p>Uncommon:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of muscle tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaw problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dropping of&nbsp; the upper and lower eyelid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision</p><p>&nbsp;</p><p>Rare:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dypsport may cause breathing difficulties</p><p>&nbsp;</p><p><strong>Treatment of children 2 years age and older with muscle spasms in the <em>leg:</em></strong></p><p><strong>&nbsp;</strong></p><p>Side effects that have occurred include:</p><p>Common:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The muscles of the lower leg may be weakened too much. This may change the way you walk or make you fall over more</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary incontinence</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&nbsp;</p><p><strong>Temporary improvement of <em>glabellar lines:</em></strong></p><p>&nbsp;</p><p>Side effects that have occurred include:</p><p>Very common:</p><ul><li>Redness, swelling, irritation, rash, itching, tingling, pain, discomfort, stinging or bruising at the site of injection</li><li>Headache</li></ul><p>Common:</p><ul><li>Tired eyes or dim vision, drooping of the upper eyelid, swelling of the eyelid, watering eyes, dry eye, twitching of muscles around the eyes</li><li>Facial paralysis</li></ul><p>Uncommon:</p><ul><li>Disturbed, blurred or double vision</li><li>Dizziness</li></ul><p>Rare:</p><ul><li>Eye movement disorder</li></ul><p>Usually these side effects, after treatment for glabellar lines, have occurred within the first week following injections and did not last long. They were usually mild to moderate in severity.</p><p>&nbsp;</p><p><strong>If any of the side effects become serious or if you notice any side effects not listed in this leaflet, please tell your doctor.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not use after the expiry date shown on the box.</p><p>&nbsp;</p><p>Dysport will be stored in a refrigerator (2&deg;C-8&deg;C) at the place where the injections are carried out. This medicine should not be given to patients to store.</p><p>&nbsp;</p><p>Chemical and physical in-use stability has been demonstrated for the reconstituted solution for 24 hours in a refrigerator (2&deg;C - 8&deg;C). After the solution is made up, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active constituent of Dysport is <em>Clostridium botulinum</em> toxin-haemagglutinin complex (500 units and 300 units). Dysport also contains human albumin and lactose. Before it is injected Dysport will be dissolved in sodium chloride for injection (a solution of salt).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dysport is a white powder in a glass vial. It comes in a pack size of 1 or 2 vials though not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The marketing authorisation holder is:</p><p>Ipsen Limited, 190 Bath Road, Slough, Berkshire, SL1 3XE, UK.</p><p>telephone: +44(0)1753627700</p><p>fax: +44 (0) 1753627701</p><p>&nbsp;</p><p>&nbsp;</p><p>Dysport is manufactured by:</p><p>Ipsen Biopharm Limited, Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 2 September 2015

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إن <strong>ديسبورت</strong> هو مادة سامة تنتجها بكتيريا الكلوستريديوم بوتولينوم. ويعمل المستحضر من خلال وقف انقباض العضلات. ويفعل هذا من خلال منع إنتاج مادة كيميائية بين الأعصاب والعضلات والتي من شأنها أن تجعل العضلات تنقبض بشكل طبيعي. وهذا يساعد على التقليل من بعض الانقباضات غير الطبيعية للعضلات المعروفة بالتشنجات.</p><p dir="RTL">يُستخدم <strong>ديسبورت</strong> للبالغين لعلاج التشنجات العضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حول العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الرقبة والكتفين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الذراع</p><p dir="RTL">كما يُستخدم <strong>ديسبورت</strong> لعلاج التشنجات في سيقان الأطفال (الذين يبلغ عمرهم عامين أو أكثر) المصابين بالشلل الدماغي، من أجل تحسين مشيهم.</p><p dir="RTL">كما قد تحتاج إلى العلاج الفيزيائي.</p><p dir="RTL">كما يمكن استخدام <strong>ديسبورت</strong> لمنع العضلات التي تسبب خطوط العبوس من الانقباض. إن استرخاء العضلات هذا مؤقت ويزول تدريجيًا. يتضايق بعض الأشخاص عندما تظهر الخطوط على وجههم. يمكن أن يُستخدَم <strong>ديسبورت</strong> للبالغين تحت سن الـ65 سنة لتحسين مظهر أيٍّ من خطوط المقطب (هي خطوط العبوس العمودية بين الحاجبين) &nbsp;التي تتراوح بين معتدلة إلى شديدة بشكل مؤقت.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم </strong><strong>ديسبورت</strong><strong> إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعلم أن لديك حساسية (شديد الحساسية) من كلوستريديوم بوتولينم توكسين أ أو أيٍّ من مكونات <strong>ديسبورت</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك التهاب في الموضع المقترح للحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مُصابًا بالوهن العضلي الوبيل، متلازمة إيتون لامبرت أو التصلب العضلي الجانبي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قم بإبلاغ</strong><strong>&nbsp;عناية خاصة عند التعامل مع </strong><strong>ديسبورت</strong></p><p dir="RTL">توجد مخاطر متزايدة لأخذ حقن <strong>ديسبورت</strong> تحت أيّ من هذه الظروف.</p><p dir="RTL">أخبر طبيبك إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أي تاريخ من التهاب الشعب الهوائية، الالتهاب الرئوي، أو مشاكل في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك رد فعل تحسسي لتوكسين البوتولينوم في الماضي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل أخرى أو أمراض تؤثر على عضلاتك مثل الوهن العضلي الوبيل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تنزف بسهولة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد خضعت لعملية جراحية في وجهك، أو من المحتمل أن تخضع لعملية جراحية في الوجه أو أية أنواع أخرى من الجراحات قريبًا (إذا كنت تفكر في علاج لخطوط المقطب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يحدث لك أي تحسن هام في خطوطك بعد علاجك الأخير (إذا كنت تفكر في علاج لخطوط المقطب).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول أحد مكونات </strong><strong>ديسبورت</strong></p><p dir="RTL">يحتوي <strong>ديسبورت</strong> على كمية صغيرة من الألبيومين والتي تم الحصول عليها من الدم البشري. لا يُمكن القضاء تمامًا على خطر انتقال عدوى من الدم عند استخدام الدم البشري أو المنتجات المصنوعة من الدم البشري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى:</strong></p><p dir="RTL">من فضلك أخبر طبيبك إذا كنت تأخذ أية مضادات حيوية لعدوى ما (على سبيل المثال: عائلة الأمينوغليكوزيد مثل جنتاميسين أو أميكاسين) أو عقاقير لاسترخاء العضلات. بعضٍ هذه الأدوية قد يزيد من تأثير توكسين البوتولينوم نوع أ.</p><p dir="RTL">من فضلك أخبر الطبيب أو الصيدلي الخاص بك إذا كنت تأخذ أو أخذت مؤخرًا أي دواء آخر، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يوصى <strong>ديسبورت</strong> أثناء الحمل، ما لم يكن ذلك ضروريًا بشكل واضح.</p><p dir="RTL">لا يوصى <strong>ديسبورت</strong> للنساء اللواتي يرضعن طبيعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، يتعين عليكِ أن تطلبي النصح من طبيبكِ قبل تناول أي دواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام للأطفال</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي أن يُستخدم <strong>ديسبورت</strong> للأطفال الذين تقل أعمارهم عن عامين. إن <strong>ديسبورت</strong> غير مناسب لعلاج خطوط المقطب لدى المرضى الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب <strong>ديسبورت</strong> ضعف العضلات أو مشاكل في رؤيتك.</p><p dir="RTL">إذا عانيت من أيٍّ من هذه الآثار، لا تقُد أو تستخدم أية آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطيك طبيبك حقنتك ويقرر عدد مرات احتياجك للعلاج. سيعتمد هذا على ما الذي تُعالج من أجله.</p><p dir="RTL">يجب أن تستخدم قنينة <strong>ديسبورت</strong> لك فقط و لجلسة علاج واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج تشنجات العضلات في <em>ذراعك</em>:</strong></p><p dir="RTL">عادة&nbsp; ما ستكون جرعة <strong>ديسبورت</strong> 1000 وحدة ولا ينبغي أن تزيد عن هذه الجرعة. يمكن للطبيب أن يُقسِّم الكمية على عضلات الذراع المصابة. وينبغي أن تتحسن تشنجاتك العضلية في غضون أسبوعين عادة. وعادة ما ستُعطى الحقن كل حوالي 12 إلى 16 أسبوعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج تشنجات العضلات في <em>رقبتك وذراعك</em>:</strong></p><p dir="RTL">عادة ما ستكون الجرعة الأولى من <strong>ديسبورت</strong> 500 وحدة. سيُقسِّم الطبيب هذه الكمية على عدد من الأماكن في الرقبة، على الأرجح على مكانين أو ثلاثة من عضلات الرقبة الأكثر تأثرًا من الحالة. وقد يتم إعطاء كمية أقل للمرضى ناقصي الوزن للغاية أو المسنين. ينبغي أن تتحسن تشنجاتك العضلية في غضون أسبوع. وسيتم إعطاء حقن إضافية (250-1000 وحدة) كل حوالي 16 أسبوعًا حسب مدة دوام التأثير أو حسب المطلوب للحفاظ على الاستجابة، ولكن ليس أكثر من مرة كل 12 أسبوعًا. ويجب أن لا تتجاوز الجرعة القصوى 1000 وحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج تشنج العضلات حول<em> عينيك</em>:</strong></p><p dir="RTL">عادة ما ستكون الحقنة الأولى 40 وحدة لكل عين. وسيتم حقن الدواء تحت الجلد مباشرة في مواضع مختلفة حول العين. إذا كانت عين واحدة فقط هي المُصابة، سيُعطي الطبيب حقن <strong>ديسبورت</strong> حول هذه العين فقط. وستُعطى الحقن حوالي كل 12 أسبوعًا حسب مدة دوام التأثير. وفي الزيارة التالية، قد تتم زيادة الكمية المُعطاة من <strong>ديسبورت</strong> إلى حد أقصاه 120 وحدة للعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج تشنج العضلات في<em> وجهك</em>:</strong></p><p dir="RTL">سيُعطيك الطبيب الحقن في الجانب المُصاب من وجهك. عادة ما ستكون الحقنة الأولى 120 وحدة. وستُعطى الحقن حوالي كل 12 أسبوعًا حسب مدة دوام التأثير. وقد يتم تقليل حقنك التالية من <strong>ديسبورت</strong> إلى 80 أو 60 وحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج الطفل المُصاب بالشلل الدماغي مع &nbsp;وجود تشنجات عضلية في <em>ساقه</em>:</strong></p><p dir="RTL">ستكون الجرعة الأولى من <strong>ديسبورت</strong> 20 وحدة لكل كيلوجرام من وزن جسم الطفل. سيُقسِّم الطبيب الكمية بين العضلتين السفليتين للساق. وإذا كانت ساق واحدة فقط هي المُصابة بالتشنجات، سيُعطي الطبيب حقن تبلغ 10 وحدات لكل كيلوجرام في هذه الساق فقط. وستُعطى الحقن حوالي كل 12 إلى 16 أسبوعًا. يمكن أن تختلف الجرعة التي يُعطيها طبيبك للطفل حسب كيفية استجابته. و ينبغي ألا تتجاوز الجرعة القصوى 1000 وحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للتحسين المؤقت <em>لخطوط المقطب</em>:</strong></p><p dir="RTL">يجب أن يُعطى <strong>ديسبورت</strong> فقط من قبل الأطباء ذوي المؤهلات والخبرات المناسبة في هذا العلاج، والذين لديهم المعدات اللازمة.</p><p dir="RTL">سيُحضِّر طبيبك الحقن ويُعطيها. يجب أن تستخدم قنينة <strong>ديسبورت</strong> لك فقط ولجلسة علاج واحدة فقط.</p><p dir="RTL">تبلغ الجرعة الموصى بها 50 وحدة، تُحقن في صورة 10 وحدات في كل موضع من مواضع الحقن الخمسة في جبينك في المنطقة التي تقع فوق أنفك وحاجبيك.</p><p dir="RTL">إن الوحدات المُستخدمة للمنتجات المختلفة من <strong>ديسبورت</strong> ليست متماثلة.</p><p dir="RTL">يجب أن يكون تأثير العلاج على شدة خطوط المقطب الخاصة بك ملحوظًا في غضون يومين إلى ثلاثة أيام. سيُقرر طبيبك الفاصل الزمني بين علاجات <strong>ديسبورت</strong>. يتعين عليك ألا تتلقى العلاج بتواتر أكثر من كل 12 أسبوعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تلقيت </strong><strong>ديسبورت</strong><strong> أكثر مما ينبغي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تلقيت <strong>ديسبورت</strong> أكثر مما تحتاج، قد تشعر بأن العضلات الأخرى غير التي تم حقنها بدأت تضعف. قد لا يحدث ذلك على الفور. إذا حدث ذلك، تحدث مع طبيبك فورًا. واطلب المساعدة الطبية العاجلة إذا كانت لديك صعوبة في التنفس، البلع أو التحدث.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت حقنة من توكسين البوتولينوم نوع أ</strong></p><p dir="RTL">لن يحدث شيء إذا تم تفويت حقنة غير أنه قد تعود بعض الانقباضات أو تصلب العضلات. أخبر طبيبك وهو سيُقرر ميعاد احتياجك للحقنة القادمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تلقي توكسين البوتولينوم نوع أ</strong></p><p dir="RTL">ستعود انقباضات عضلاتك إلى الحال الذي كانت عليه قبل العلاج.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يُسبب <strong>ديسبورت</strong> آثارًا جانبية، على الرغم من أنها لا تُصيب الجميع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك <strong>على الفور</strong> إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك أية مشاكل في البلع، التنفس، أو التحدث.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من مشاكل في التنفس مع أو من دون تورم في الوجه، الشفتين، اللسان و/أو الحلق، احمرار الجلد أو طفح جلدي كتلي حاك (حساسية). فقد يعني ذلك أنك تعاني من رد فعل تحسسي لتوكسين البوتولينوم نوع أ.</p><p dir="RTL">إن فرصة المعاناة من أثر جانبي مشروحة من خلال المجموعات التالية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>مدى تكرار حدوثه</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شائع للغاية</p></td><td style="vertical-align:top"><p dir="RTL">يحدث لدى أكثر من مريض بين كل 10 أفراد من المرضى المُعالجين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">يحدث لدى أقل من مريض بين كل 10 أفراد من المرضى المُعالجين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غير شائع</p></td><td style="vertical-align:top"><p dir="RTL">يحدث لدى أقل من مريض بين كل 100 فرد من المرضى المُعالجين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نادر</p></td><td style="vertical-align:top"><p dir="RTL">يحدث لدى أقل من مريض بين كل 1000 فرد من المرضى المُعالجين.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث بعض الآثار الجانبية لدى أي مريض يُعالج بتوكسين البوتولينوم نوع أ، بينما قد تعتمد آثارًا جانبية أخرى على الحالة التي يتم علاجها. تأكد من قراءة جميع الأقسام التي تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج أية حالة <em>(جميع المرضى)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية التي حدثت:</p><p dir="RTL">آثار جانبية شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات أو ألم حول الموضع الذي أُعطيت الحقنة فيه، أو الإحساس بحرقان في وقت إعطاء الحقنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبه أعراض الانفلونزا.</p><p dir="RTL">آثار جانبية غير شائعة: الحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية نادرة: طفح جلدي وضعف العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما تم الإبلاغ عن حدوث آثار جانبية أخرى متعلقة بانتشار <strong>ديسبورت</strong> بعيدًا عن موضع الحقن (ضعف متفاقم في العضلات، صعوبة في البلع أو التنفس التي كانت مميتة في حالات نادرة للغاية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج تشنجات العضلات في <em>الذراع</em>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية التي حدثت:</p><p dir="RTL">آثار جانبية شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في عضلات الذراع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابات/سقطات عرضية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج تشنجات العضلات في <em>العينين أو الوجه</em>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية التي حدثت:</p><p dir="RTL">آثار جانبية شائعة للغاية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدلي الجفون.</p><p dir="RTL">آثار جانبية شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العينين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواجية الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دموع أكثر من المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عضلات الوجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية غير شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشلل الوجهي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية نادرة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في تحريك العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تنقلب حافة الجفن للداخل في اتجاه مقلة العين وقد تُصاب عضلات العين بالشلل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك <strong>على الفور</strong> إذا لاحظت جفافًا شديدًا في العينين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج تشنجات العضلات في <em>الرقبة والكتفين</em>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية التي حدثت:</p><p dir="RTL">آثار جانبية شائعة للغاية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع. من المتوقع أن يزول هذا الأثر الجانبي في غضون أسبوعين إلى أربعة أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p dir="RTL">آثار جانبية شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية أو مشاكل أخرى في الرؤية بوضوح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الرقبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في عضلات الوجه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والعظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في اليدين والأصابع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في نبرة الصوت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية غير شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان النسيج العضلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الفك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدلي الجفن العلوي والسفلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية نادرة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُسبب <strong>ديسبورت</strong> صعوبات في التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج الأطفال المصابين ب</strong><strong>تشنجات عضلية في <em>الساق</em></strong><strong> والذين تبلغ أعمارهم سنتين أو أكثر:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية التي حدثت:</p><p dir="RTL">آثار جانبية شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تضعف عضلات الجزء الأسفل من الساق كثيرًا. وهذا قد يُغير من طريقة مشيك أو قد يجعلك تقع بشكل أكبر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلس البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL"><strong>تحسن مؤقت في خطوط المقطب:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية التي حدثت:</p><p dir="RTL">آثار جانبية شائعة للغاية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار، التورم، التهيج، الطفح الجلدي، الحكة، الوخز الخفيف، الألم، عدم الراحة، وخز أو كدمات في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&nbsp;آثار جانبية شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب العينين أو رؤية ضبابية، تدلي الجفن العلوي، تورم الجفن، العيون الدامعة، جفاف العينين، ارتعاش العضلات حول العينين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شلل وجهي.</p><p dir="RTL">آثار جانبية غير شائعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب، عدم وضوح، أو ازدواج الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار.</p><p dir="RTL">آثار جانبية نادرة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حركة العين.</p><p dir="RTL">عادة ما تكون هذه الآثار الجانبية - بعد العلاج لخطوط المقطب - قد حدثت في غضون الأسبوع الأول الذي يلي الحقن ولا تدوم طويلاً. وكانت تتراوح شدتها عادة بين خفيفة إلى معتدلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجى إخبار طبيبك، إذا أصبحت أيّ من الآثار الجانبية خطيرة، أو إذا لاحظت أية آثار جانبية غير مُدرجة في هذه النشرة.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ بعيدًا عن متناول وبصر الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدمه بعد تاريخ انتهاء الصلاحية الموجود على العلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيُخزَّن <strong>ديسبورت</strong> في ثلاجة (درجتين-ثماني درجات مئوية) في المكان الذي تُعطى فيه الحقن. لا ينبغي أن يُعطى هذا الدواء للمرضى كي يقوموا بتخزينه.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي للمحلول المعاد تشكيله لمدة 24 ساعة في الثلاجة عند 2-8</p><p dir="RTL">درجة مئوية . ينبغي استخدام المنتج على الفور بعد تجهيز المحلول، ما لم تكن -</p><p dir="RTL">طريقة تجهيز المحلول تحول دون خطر التلوث الميكروبي. إذا لم يُستخدم المنتج على الفور،</p><p dir="RTL">تخضع أوقات وظروف التخزين قبل الاستخدام لمسؤولية المستخدم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المكوّن النشط<strong> ديسبورت</strong> هو مُركب توكسين كلوستريديوم البوتولينوم - الهيماغلوتينين (500 وحدة و 300 وحدة). كما يحتوي <strong>ديسبورت </strong>على دم بشري ولاكتوز. سيتم تذويب <strong>ديسبورت</strong> - قبل أن يُحقن - في كلوريد الصوديوم (محلول من الملح) من أجل الحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ب.كيف يبدو </strong><strong>ديسبورت</strong><strong> وما هي محتويات الحزمة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يكون <strong>ديسبورت</strong> دائمًا مسحوقًا أبيضًا في قنينة زجاجية. وتحتوي كل حزمة على قنينة أو قنينتين من <strong>ديسبورت،</strong> مع العلم أنه يمكن ان لا تتوفر جميع احجام العبوات في السوق.<strong> </strong>&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل ترخيص التسويق هو:</p><p dir="RTL">ابسن المحدودة، 190 شارع باث، سلوف، بيركشاير، SL1 3XE، المملكة المتحدة.</p><p dir="ltr">هاتف:&nbsp; &nbsp;4401753627700</p><p dir="RTL">فاكس:&nbsp; 1753627701(0)44+&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تصنيع <strong>ديسبورت</strong> بواسطة:</p><p>ابسن بايوفارما المحدودى، آش روود، منطقة ريكسهام الصناعية، ريكسهام LL13 9UF</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 2 سبتمبر 2015

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dysport powder for solution for injection. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clostridium botulinum type A toxin-haemagglutinin complex 500 units*
*One unit (U) is defined as the median lethal intraperitoneal dose in mice.
For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dysport is indicated for focal spasticity, including the treatment of:</p><p>-&nbsp; arm symptoms associated with focal spasticity in conjunction with physiotherapy;</p><p>and</p><p>-&nbsp; dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, two years of age or older, only in hospital specialist centres with appropriately trained personnel.</p><p>Dysport is also indicated for the following treatments:</p><p>-&nbsp; Spasmodic torticollis in adults</p><p>-&nbsp; Blepharospasm in adults</p><p>-&nbsp; Hemifacial spasm in adults</p><p>-&nbsp; The temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at frown, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The units of Dysport are specific to the preparation and are not interchangeable with other preparations of botulinum toxin. <strong>&nbsp;</strong></p><p>Training: Dysport should only be administered by appropriately trained physicians.</p><p>Ipsen can facilitate training in administration of Dysport injections .</p><p>The exposed central portion of the rubber stopper should be cleaned with alcohol immediately prior to piercing the septum.&nbsp; A sterile 23 or 25 gauge needle should be used.</p><p><strong><em>Arm spasticity:</em></strong></p><p><u>Posology</u></p><p>The recommended dose is 1000 units in total, distributed amongst the following five muscles:</p><table border="1" cellspacing="0" cellpadding="0" style="width:539px"><tbody><tr><td style="vertical-align:top"><p>Biceps brachii</p><p>(BB)</p></td><td style="vertical-align:top"><p>Flexor digitorum profundus</p><p>(FDP)</p></td><td style="vertical-align:top"><p>Flexor digitorum superficialis</p><p>(FDS)</p></td><td style="vertical-align:top"><p>Flexor carpi ulnaris</p><p>(FCU)</p></td><td style="vertical-align:top"><p>Flexor carpi radialis</p><p>(FCR)</p></td><td style="vertical-align:top"><p>Total Dose</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>300-400 units</p><p>(0.6-0.8mL)</p></td><td style="vertical-align:top"><p>150 units</p><p>(0.3mL)</p></td><td style="vertical-align:top"><p>150-250 units</p><p>(0.3-0.5mL)</p></td><td style="vertical-align:top"><p>150 units</p><p>(0.3mL)</p></td><td style="vertical-align:top"><p>150 units</p><p>(0.3mL)</p></td><td style="vertical-align:top"><p>1,000 units</p><p>(2.0mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>The sites of injection should be guided by standard locations used for electromyography (EMG), although actual location of the injection site will be determined by palpation.&nbsp; All muscles except the biceps brachii (BB) should be injected at one site, whilst the biceps should be injected at two sites. The maximum dose administered must not exceed 1000 units.&nbsp;</p><p>The starting dose should be lowered if there is evidence to suggest that this dose may result in excessive weakness of the target muscles, such as for patients whose target muscles are small, where the BB muscle is not to be injected or for patients who&nbsp; require concomitant injections into other muscle groups. Clinical improvement may be expected within two weeks after injection.<strong> </strong>Injections may be repeated approximately every 16 weeks, or as required to maintain a response, but not more frequently than every 12 weeks.</p><p><em>Children: </em>The safety and effectiveness of Dysport in the treatment of arm spasticity in children have not been demonstrated.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Method of administration</u></p><p>When treating arm spasticity, Dysport is reconstituted with 1.0mL of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per mL of Dysport.</p><p>Dysport is administered by intramuscular injection into the five muscles detailed above when treating arm spasticity.</p><p><strong><em>Paediatric cerebral palsy spasticity</em></strong><strong>:</strong></p><p><u>Posology</u></p><p>The initial recommended dose is 20 units/kg body weight given as a divided dose between both calf muscles.&nbsp; If only one calf is affected, a dose of 10 units/kg body weight should be used. Consideration should be given to lowering this starting dose if there is evidence to suggest that this dose may result in excessive weakness of the target muscles, such as for patients whose target muscles are small or patients who require concomitant injections to other muscle groups.<strong>&nbsp; </strong>Following evaluation of response to the starting dose subsequent treatment may be titrated within the range 10 units/kg and 30 units/kg divided between both legs. The maximum dose administered must not exceed 30units /kg or 1000 units/patient, whichever is the lower.&nbsp;</p><p>Administration should primarily be targeted to the gastrocnemius, although injections of the soleus and injection of the tibialis posterior should also be considered.</p><p>The use of electromyography (EMG) is not routine clinical practice but may assist in identifying the most active muscles.</p><p>Clinical improvement may be expected within two weeks after injection. Injections may be repeated approximately every 16 weeks or as required to maintain response,<strong> </strong>but not more frequently than every 12 weeks.<strong>&nbsp; </strong></p><p><u>Method of administration</u></p><p>When treating paediatric cerebral palsy spasticity, Dysport is reconstituted with 1.0mL of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per mL of Dysport.&nbsp;</p><p>Dysport is administered by intramuscular injection into the calf muscles when treating spasticity.</p><p><em>Spasmodic torticollis:</em></p><p><u>Posology</u></p><p>The doses recommended for torticollis are applicable to adults of all ages providing the adults are of normal weight with no evidence of low neck muscle mass. A reduced dose may be appropriate if the patient is markedly underweight or in the elderly, where reduced muscle mass may exist.</p><p>The initial recommended dose for the treatment of spasmodic torticollis is 500 units per patient given as a divided dose and administered to the two or three most active neck muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For rotational torticollis distribute the 500 units by administering 350 units into the splenius capitis muscle, ipsilateral to the direction of the chin/head rotation and 150 units into the sternomastoid muscle, contralateral to the rotation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For laterocollis, distribute the 500 units by administering 350 units into the ipsilateral splenius capitis muscle and 150 units into the ipsilateral sternomastoid muscle. In cases associated with shoulder elevation the ipsilateral trapezoid or levator scapulae muscles may also require treatment, according to visible hypertrophy of the muscle or electromyographic (EMG) findings. Where injections of three muscles are required, distribute the 500 units as follows, 300 units splenius capitis, 100 units sternomastoid and 100 units to the third muscle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For retrocollis distribute the 500 units by administering 250 units into each of the splenius capitis muscles. Bilateral splenii injections may increase the risk of neck muscle weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All other forms of torticollis are highly dependent on specialist knowledge and EMG to identify and treat the most active muscles. EMG should be used diagnostically for all complex forms of torticollis, for reassessment after unsuccessful injections in non complex cases, and for guiding injections into deep muscles or in overweight patients with poorly palpable neck muscles.</p><p>On subsequent administration, the doses may be adjusted according to the clinical response and side effects observed. Doses within the range of 250-1000 units are recommended, although the higher doses may be accompanied by an increase in side effects, particularly dysphagia. The maximum dose administered must not exceed 1000 units.</p><p>&nbsp; The relief of symptoms of torticollis may be expected within a week after the injection.</p><p>&nbsp; Injections may be repeated approximately every 16 weeks or as required to maintain a response, but not more frequently than every 12 weeks.<s>&nbsp; </s></p><p><em>Children: </em>The safety and effectiveness of Dysport in the treatment of spasmodic torticollis in children have not been demonstrated.</p><p><u>Method of administration</u></p><p>When treating spasmodic torticollis Dysport is reconstituted with 1.0mL of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per mL of Dysport.</p><p>Dysport is administered by intramuscular injection as above when treating spasmodic torticollis.</p><p>&nbsp;</p><p>&nbsp;</p><p>Blepharospasm and hemifacial spasm</p><p><u>Posology</u></p><p>In a dose ranging clinical trial on the use of Dysport for the treatment of benign essential blepharospasm, a dose of 40 units per eye was significantly effective.&nbsp; Doses of 80 units and 120 units per eye resulted in a longer duration of effect.&nbsp; However, the incidence of local adverse events, specifically ptosis, was dose related. In the treatment of blepharospasm and hemifacial spasm, the maximum dose used must not exceed a total dose of 120&nbsp;units per eye. <s>&nbsp;</s></p><p>An injection of 10 units (0.05mL) medially and 10 units (0.05mL) laterally should be made into the junction between the preseptal and orbital parts of both the upper (3 and 4) and lower <em>orbicularis oculi</em> muscles (5 and 6) of each eye. In order to reduce the risk of ptosis, injections near the <em>levator palpebrae superioris</em> should be avoided.</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="609" height="802" vspace="0" hspace="0" border="0" style="width:609px;height:802px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>For injections into the upper lid the needle should be directed away from its centre to avoid the levator muscle. A diagram to aid placement of these injections is provided. The relief of symptoms may be expected to begin within two to four days with maximal effect within two weeks.</p><p>Injections should be repeated approximately every twelve weeks or as required to prevent recurrence of symptoms but not more frequently than every twelve weeks. On such subsequent administrations, if the response from the initial treatment is considered insufficient, the dose per eye may need to be increased to 60 units: 10 units (0.05mL) medially and 20 units (0.1mL) laterally, 80 units: 20 units (0.1mL) medially and 20 units (0.1mL) laterally or up to 120 units: 20 units (0.1mL) medially and 40 units (0.2mL) laterally above and below each eye in the manner previously described. Additional sites in the frontalis muscle above the brow (1 and 2) may also be injected if spasms here interfere with vision.</p><p>In cases of unilateral blepharospasm the injections should be confined to the affected eye. Patients with hemifacial spasm should be treated as for unilateral blepharospasm. The doses recommended are applicable to adults of all ages including the elderly.</p><p><em>Children: </em>The safety and effectiveness of Dysport in the treatment of blepharospasm and hemifacial spasm in children have not been demonstrated.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>When treating blepharospasm and hemifacial spasm, Dysport is reconstituted with 2.5mL of sodium chloride injection BP (0.9%) to yield a solution containing 200 units per mL of Dysport.</p><p>Dysport is administered by subcutaneous injection medially and laterally into the junction between the preseptal and orbital parts of both the upper and lower orbicularis oculi muscles of the eyes.</p><p><strong><em>Glabellar Lines:</em></strong></p><p><u>Posology and method of administration</u></p><p>Once reconstituted, Dysport should only be used to treat a single patient, during a single session.</p><p>Prior to injection, the product should be reconstituted, instructions for which are given in Section 6.6.</p><p>Remove any make-up and disinfect the skin with a local antiseptic.</p><p>Intramuscular injections should be performed at right angles to the skin using a sterile 29-30 gauge needle.</p><p>The recommended dose is 50 units (0.25mL of reconstituted solution) of Dysport to be divided into 5 injection sites, 10 units (0.05mL of reconstituted solution) are to be administered intramuscularly into each of the 5 sites: 2 injections into each corrugator muscle and one into the procerus muscle near the nasofrontal angle as shown below:</p><p><img src="data:image/png;base64,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" alt="" width="609" height="802" vspace="0" hspace="0" border="0" style="width:609px;height:802px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p>The anatomical landmarks can be more readily identified if observed and palpated at maximal frown. Before injection, place the thumb or index finger firmly below the orbital rim in order to prevent extravasation below the orbital rim. The needle should be pointed upward and medially during the injection. In order to reduce the risk of ptosis, avoid injections near the levator palpebrae superioris muscle, particularly in patients with larger brow-depressor complexes (depressor supercilii). Injections in the corrugator muscle must be made into the central part of that muscle, at least 1cm above the orbital rim.</p><p>The treatment interval depends on the individual patient&rsquo;s response after assessment. In clinical studies, an optimal effect was demonstrated for up to 4 months after injection. Some patients were still responders at 5 months. Treatment interval should not be more frequent than every three months.</p><p>In the event of treatment failure or diminished effect following repeat injections, alternative treatment methods should be employed. In case of treatment failure after the first treatment session, the following approaches may be considered:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Analysis of the causes of failure, e.g. incorrect muscles injected, injection technique, and formation of toxin-neutralising antibodies;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Re-evaluation of the relevance of treatment with Dysport</p><p><em>Children</em></p><p>The safety and effectiveness of Dysport in treating glabellar lines in individuals under 18 years of age have not been demonstrated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dysport is contraindicated in individuals with known hypersensitivity to any components of Dysport.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects related to spread of toxin distant from the site of administration have been reported (see section 4.8) which, in some cases, were associated with dysphagia, pneumonia and/or significant debility resulting, very rarely, in death. Patients treated with therapeutic doses may present with excessive muscle weakness. The risk of occurrence of such undesirable effects may be reduced by using the lowest effective possible dose and by not exceeding the maximum recommended dose.</p><p>Dysport should only be used with caution and under close medical supervision in patients with subclinical or clinical evidence of marked defective neuromuscular transmission<strong> </strong>(e.g. myasthenia gravis). Such patients may have an increased sensitivity to agents such as Dysport, which may result in excessive muscle weakness with therapeutic doses. Patients with underlying neurological disorders are at increased risk of this side effect.</p><p>Very rare cases of death, occasionally in the context of dysphagia, pneumopathy and/or in patients with significant asthenia have been reported following treatment with botulinum toxin A or B.&nbsp; Patients with disorders resulting in defective neuromuscular transmission, difficulty in swallowing or breathing are more at risk of experiencing these effects.&nbsp; In these patients, treatment must be administered under the control of a specialist and only if the benefit of treatment outweighs the risk.</p><p>Dysport should be administered with caution to patients with pre-existing swallowing or breathing problems as these can worsen following the distribution of the effect of toxin into the relevant muscles.&nbsp; Aspiration has occurred in rare cases and is a risk when treating patients who have a chronic respiratory disorder.</p><p>The recommended posology and frequency of administration for Dysport must not be exceeded (see section 4.2).</p><p>Patients and their care-givers must be warned of the necessity to seek immediate medical treatment in case of problems with swallowing, speech or respiratory problems.&nbsp;</p><p>For the treatment of spasticity associated with cerebral palsy in children, Dysport should only be used in children of 2 years of age or over.</p><p>Dysport should not be used to treat spasticity in patients who have developed a fixed contracture.</p><p>As with any intramuscular injection, Dysport should only be used where strictly necessary in patients with prolonged bleeding times, infection or inflammation at the proposed site(s) of injection.</p><p>Dysport should only be used to treat a single patient, during a single session. Specific precautions must be taken during the preparation and administration of the product (see section 4.2) and for the inactivation and disposal of any unused reconstituted solution (see section 6.6).</p><p>This product contains a small amount of human albumin. The risk of transmission of viral infection cannot be excluded with absolute certainty following the use of human blood or blood products.</p><p>Antibody formation to botulinum toxin has been noted rarely in patients receiving Dysport. Clinically, neutralising antibodies might be suspected by a substantial deterioration in response to therapy and /or the need for consistent use of increased doses.</p><p>When treating glabellar lines, it is essential to study the patient&rsquo;s facial anatomy prior to administration. Facial asymmetry, ptosis, excessive dermatochalasis, scarring and any alterations to this anatomy, as a result of previous surgical interventions should be taken into consideration. Caution should be taken when the targeted muscle shows excessive weakness or atrophy.</p><p>Careful consideration should be given before the injection of patients who have experienced a previous allergic reaction to a product containing botulinum toxin type A. The risk of a further allergic reaction must considered in relation to the benefit of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of botulinum toxin may be potentiated by drugs interfering either directly or indirectly with the neuromuscular function (e.g. aminoglycosides, curare-like non-depolarising blockers) and such drugs should be used with caution in patients treated with botulinum toxin.</p><p><s>&nbsp;</s></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy:</p><p>There are limited data from the use of <em>Clostridium botulinum</em> type A toxin-haemagglutinin complex in pregnant women. Studies in animals have shown reproductive toxicity at doses causing maternal toxicity (see section 5.3).</p><p>Dysport should be used during pregnancy only if the benefit justifies any potential risk to the f&oelig;tus. Caution should be exercised when prescribing to pregnant women.</p><p>Lactation:</p><p>It is not known whether <em>Clostridium botulinum</em> type A toxin-haemagglutinin complex is excreted in human milk. The excretion of <em>Clostridium botulinum</em> type A toxin-haemagglutinin complex in milk has not been studied in animals. The use of <em>Clostridium botulinum</em> type A toxin-haemagglutinin complex during lactation cannot be recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is a potential risk of muscle weakness or visual disturbances which, if experienced, may temporarily impair the ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Very common &gt;1/10: Common &gt;1/100, &lt;1/10: Uncommon &gt;1/1000, &lt;1/100:</p><p>Rare &gt;1/10 000, &lt; 1/1000: Very rare &lt;1/10 000.</p><p>Side effects related to spread of toxin distant from the site of administration have been reported (exaggerated muscle weakness, dysphagia, aspiration/aspiration pneumonia, with fatal outcome in some very rare cases).&nbsp;</p><p>(see section 4.4).</p><p><strong><em>General</em></strong></p><p>In the clinical trial programme, approximately 28% of the patients treated with Dysport experienced an adverse event.</p><p>The following adverse reactions were seen in patients treated across a variety of indications including blepharospasm, hemifacial spasm, torticollis and spasticity associated with either cerebral palsy or stroke:</p><p><em>Nervous system disorders</em></p><p>Rare: Neuralgic amyotrophy</p><p>Skin and subcutaneous tissue disorders</p><p>Uncommon: Itching</p><p>Rare: Skin rashes</p><p>General disorders and administration site conditions</p><p>Common: Generalised weakness, fatigue, flu-like syndrome, pain / bruising at injection site.</p><p>In addition, the following adverse reactions specific to individual indications were reported:</p><p>Arm spasticity</p><p>Gastrointestinal disorders</p><p>Common: Dysphagia</p><p>Musculoskeletal and connective tissue disorders</p><p>Common: Arm muscle weakness</p><p>Injury, poisoning and procedural complications</p><p>Common: Accidental injury/falls</p><p><em>Paediatric cerebral palsy spasticity</em></p><p>Gastrointestinal disorders</p><p>Common: Diarrhoea <s>&nbsp;</s></p><p>Musculoskeletal and connective tissue disorders</p><p>Common: Leg muscle weakness, muscle pain</p><p>Renal and urinary disorders</p><p>Common: Urinary incontinence</p><p>General disorders and administration site conditions</p><p>Common: Abnormal gait</p><p>Injury, poisoning and procedural complications</p><p>Common: Accidental injury due to falling</p><p>Accidental injury due to falling and abnormal gait may have been due to the over-weakening of the target muscle and / or the local spread of Dysport to other muscles involved in ambulation and balance.</p><p><em>Spasmodic torticollis</em></p><p>Nervous system disorders</p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>Common: Headache, dizziness, facial pareis</p><p>Eye disorders</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: Blurred vision, visual acuity reduced</p><p>Uncommon: Diplopia, ptosis</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Common: Dysphonia, dyspnoea</p><p>Rare: Aspiration</p><p>Gastrointestinal disorders</p><p>Very common: Dysphagia, dry mouth</p><p>Musculoskeletal and connective tissue disorders</p><p>Very Common: Muscle weakness</p><p>Common: Neck pain, musculoskeletal pain, myalgia, pain in extremity musculoskeletal stiffness</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: Muscle atrophy, jaw disorder</p><p>Dysphagia appeared to be dose related and occurred most frequently following injection into the sternomastoid muscle. A soft diet may be required until symptoms resolve.</p><p>These side effects may be expected to resolve within two to four weeks.</p><p>Blepharospasm and hemifacial spasm</p><p><em>Nervous system disorders</em></p><p>Common: Facial muscle weakness</p><p>Uncommon: Facial&nbsp; paralysis</p><p>Eye disorders</p><p>Very common: Ptosis</p><p>Common: Diplopia, dry eyes, tearing</p><p>Rare: Ophthalmoplegia</p><p>Skin and subcutaneous tissue disorders</p><p>Common: Eyelid oedema</p><p>Rare: Entropion</p><p>Side effects may occur due to deep or misplaced injections of Dysport temporarily paralysing other nearby muscle groups.</p><p><strong><em>Glabellar Lines</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:526px"><tbody><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><u>Very Common</u></p><p>Headache</p><p><u>Common</u></p><p>Facial paresis (predominantly describes brow paresis)</p><p><u>Uncommon</u></p><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Asthenopia, Ptosis, Eyelid oedema, Lacrimation increase, Dry eye, Muscle twitching (twitching of muscles around the eyes)</p><p><u>Uncommon</u></p><p>Visual disturbances, Vision blurred, Diplopia</p><p><u>Rare</u></p><p>Eye movement disorder</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Pruritus, Rash</p><p><u>Rare</u></p><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><u>Very Common</u></p><p>Injection site reactions (e.g. erythema, oedema, irritation, rash, pruritus, paraesthesia, pain, discomfort, stinging and bruising)</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Hypersensitivity</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Post-marketing experience</u></strong></p><p>The profile of adverse reactions reported to the Company during post-marketing use reflects the pharmacology of the product and those seen during clinical trials.&nbsp; In addition, hypersensitivity reactions have been reported.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excessive doses may produce distant and profound neuromuscular paralysis. Overdose could lead to an increased risk of the neurotoxin entering the bloodstream and may cause complications associated with the effects of oral botulinum poisoning (e.g dysphagia and dysphonia).&nbsp; Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. There is no specific antidote; antitoxin should not be expected to be beneficial and general supportive care is advised.&nbsp; In the event of overdose the patient should be medically monitored for signs and /or symptoms of excessive muscle weakness or muscle paralysis.&nbsp; Symptomatic treatment should be instigated if necessary.</p><p>Symptoms of overdose may not present immediately following injection.&nbsp; Should accidental injection or oral ingestion occur, the person should be medically supervised for several weeks for signs and/or symptoms of excessive muscle weakness or muscle paralysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Other muscle relaxants, peripherally acting agents.</p><p>ATC code: M03AX01</p><p><em>Clostridium botulinum</em> type A toxin-haemagglutinin complex blocks peripheral cholinergic transmission at the neuromuscular junction by a presynaptic action at a site proximal to the release of acetylcholine. The toxin acts within the nerve ending to antagonise those events that are triggered by Ca<sup>2+</sup> which culminate in transmitter release. It does not affect postganglionic cholinergic transmission or postganglionic sympathetic transmission.</p><p>The action of toxin involves an initial binding step whereby the toxin attaches rapidly and avidly to the presynaptic nerve membrane. Secondly, there is an internalisation step in which toxin crosses the presynaptic membrane, without causing onset of paralysis. Finally the toxin inhibits the release of acetylcholine by disrupting the Ca<sup>2+</sup> mediated acetylcholine release mechanism, thereby diminishing the endplate potential and causing paralysis.</p><p>Recovery of impulse transmission occurs gradually as new nerve terminals sprout and contact is made with the post synaptic motor endplate, a process which takes 6 - 8 weeks in the experimental animal.</p><p>Alternative Dysport doses were investigated for the treatment of blepharospasm over 1 treatment cycle in a clinical study.</p><p>Efficacy was measured by the medians of differences in the Percentage of Normal Activity (PNA) values (derived from the Blepharospasm Disability Scale) between each treatment group and placebo. A dose-dependent improvement in blepharospasm was evident with increasing Dysport dose, with all treatment groups being superior to placebo.&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p>Visit</p></td><td style="vertical-align:top"><p>Dysport 40 Units</p><p>(N=30)</p></td><td style="vertical-align:top"><p>Dysport 80 Units</p><p>(N=31)</p></td><td style="vertical-align:top"><p>Dysport 120 Units</p><p>(N=31)</p></td></tr><tr><td style="vertical-align:top"><p>Week 4:</p><p>Difference between the median of the changes in PNA values from baseline in the active group and the median of the changes in PNA values from baseline in the placebo group</p><p>&nbsp;</p></td><td><p>31.2 %</p></td><td><p>41.3 %</p></td><td><p>48.5 %</p></td></tr><tr><td style="vertical-align:top"><p>Week 8:</p><p>Difference between the median of the changes in PNA values from baseline in the active group and the median of the changes in PNA values from baseline in placebo group</p><p>&nbsp;</p></td><td><p>36.0 %</p></td><td><p>48.3 %</p></td><td><p>55.0 %</p></td></tr><tr><td style="vertical-align:top"><p>Week 12:</p><p>Difference between the median of the changes in PNA values from baseline in the active group and the median of the changes in PNA values from baseline in placebo group</p><p>&nbsp;</p></td><td><p>36.0 %</p></td><td><p>36.3 %</p></td><td><p>50.0 %</p></td></tr><tr><td style="vertical-align:top"><p>Week 16:</p><p>Difference between the median of the changes in PNA values from baseline in the active group and the median of the changes in PNA values from baseline in placebo group</p><p>&nbsp;</p></td><td><p>10.5 %[<!--[if supportFields]><span
  style='mso-bookmark:CTDTable002_1'></span><span style='mso-element:field-begin'></span><span
  style='mso-bookmark:CTDTable002_1'><span style='font-size:12.0pt'> SEQ
  CTDTable002 \* alphabetic \* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:CTDTable002_1'></span><span style='mso-element:field-end'></span><![endif]-->]</p></td><td><p>24.2 %</p></td><td><p>31.3 %</p></td></tr></tbody></table><p>[<!--[if supportFields]><span style='font-size:
12.0pt;mso-bidi-language:NE-IN'><span style='mso-element:field-begin'></span>
SEQ CTDTable002 CTDTable002_1 \* alphabetic \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->a<!--[if supportFields]><span style='font-size:12.0pt;
mso-bidi-language:NE-IN'><span style='mso-element:field-end'></span></span><![endif]-->]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p value &gt; 0.001</p><p>&nbsp;</p><p>For the 40 units, 80 units and 120 units Dysport treatment groups, the medians of the changes from baseline in PNA values were statistically significantly higher compared to those in placebo group at weeks 4, 8, and 12.</p><p>A statistically significant difference compared to placebo group was also observed for the 80 units and 120 units Dysport treatment groups at week 16, indicating a greater duration of response at the 80 units and 120 units doses.</p><p>The incidence of related Treatment Emergent Adverse Events (TEAEs), specifically ptosis, was higher in the Dysport treatment groups than in the placebo treatment group and was dose-dependent with greater incidence seen at higher Dysport doses. See table below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:597px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Statistic</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=26)</p></td><td style="vertical-align:top"><p>Dysport 40 Units</p><p>(N=31)</p></td><td style="vertical-align:top"><p>Dysport 80 Units</p><p>(N=31)</p></td><td style="vertical-align:top"><p>Dysport 120 Units</p><p>(N=31)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with related TEAEs</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3 (12)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19 (61)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23 (74)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>26 (84)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Patients with related eye TEAEs</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3 (12)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16 (52)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23 (74)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>26 (84)</p></td></tr></tbody></table><p style="text-indent:50px">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic studies with botulinum toxin pose problems in animals because of the high potency, the minute doses involved, the large molecular weight of the compound and the difficulty of labelling toxin to produce sufficiently high specific activity. Studies using I<sup>125</sup> labelled toxin have shown that the receptor binding is specific and saturable, and the high density of toxin receptors is a contributory factor to the high potency. Dose and time responses in monkeys showed that at low doses there was a delay of 2 - 3 days with peak effect seen 5 - 6 days after injection. The duration of action, measured by changes of ocular alignment and muscle paralysis, varied between 2 weeks and 8&nbsp;months. This pattern is also seen in man, and is attributed to the process of binding, internalisation and changes at the neuromuscular junction.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reproductive toxicity studies in pregnant rats and rabbits given <em>Clostridium botulinum </em>type A toxin-haemagglutinin complex by daily intramuscular injection, at doses of 6.6&nbsp;units/kg (79 units/kg total cumulative dose) and 3.0 units/kg (42&nbsp;units/kg total cumulative dose) in rats and rabbits respectively, did not result in embryo/foetal toxicity. Implantation losses at maternally toxic doses were observed at higher doses in both species. <em>Clostridium botulinum </em>type A toxin-haemagglutinin complex demonstrated no teratogenic activity in either rats or rabbits and no effects were observed in the pre- and postnatal study on the F1 generation in rats. Fertility of male and female rats was decreased due to reduced mating secondary to muscle paralysis at doses of 29.4 units/kg weekly in males and increased implantation loss at 20 units/kg weekly in females.</p><p>In a chronic toxicity study performed in rats up to 12&nbsp;units/animal, there was no indication of systemic toxicity. Effects in chronic toxicity non-clinical studies were limited to changes on injected muscles related to the mechanism of action of <em>Clostridium botulinum </em>type A toxin-haemagglutinin complex. There was no ocular irritation following administration of <em>Clostridium botulinum </em>type A toxin-haemagglutinin complex into the eyes of rabbits<strong>. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human albumin solution,</p><p>Lactose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial:
2 years 

Reconstituted solution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C. 

From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Unopened vial:</em></strong></p><p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Do not freeze.</p><p><strong><em>Reconstituted solution:</em></strong></p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Nature of container/closure:</em></strong></p><p>Type 1 glass vials 3mL capacity. 13mm bromobutyl freeze-drying closures oversealed by 13mm aluminium overseals with centre hole, crimped over.</p><p><strong><em>Contents of container:</em></strong></p><p>A white lyophilised powder for reconstitution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediately after treatment of the patient, any residual Dysport which may be present in either vial or syringe should be inactivated with dilute hypochlorite solution (1% available chlorine). Thereafter, all items should be disposed of in accordance with standard hospital practice.</p><p>Spillage of Dysport should be wiped up with an absorbent cloth soaked in dilute hypochlorite solution.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ipsen Limited
190 Bath Road, 
Slough
Berkshire, SL1 3XE
United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 September 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>